{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034846","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.312660+00:00","generated_at":"2026-05-16T20:28:22.252801+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track","bullets":["Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.","Cash and cash equivalents totaled $13.2M as of September 30, 2025.","Pre-NDA meeting with FDA planned for Q4 2025; NDA submission for schizophrenia targeted for Q2 2026.","European patent granted covering use of brilaroxazine for treatment of pulmonary fibrosis.","Closed public equity offering with gross proceeds of $9.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034846","json":"https://secwatch.observer/filing/0001437749-25-034846.json","markdown":"https://secwatch.observer/filing/0001437749-25-034846.md","text":"https://secwatch.observer/filing/0001437749-25-034846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/0001437749-25-034846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/rvph20251103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:28:22.252801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}